fig1

Figure 1. Overall Survival probability according to time after therapy initiation in the study population, divided by time to first-line VEGFR-TKI monotherapy failure. Patients who progressed in less than 3 months from therapy start are labeled “primary refractory”, patients who progressed between 3 and 6 months are labeled “primary resistant”, and patients who progressed beyond 6 months from therapy start are labeled “responder”.